Michael Ehrenstein

Validation and mechanistic insights for IgA2 as a companion biomarker of combination belimumab after rituximab for #lupus supporting the upcoming STRATIFY lupus trial cell.com/cell-reports-m…

A very productive 2-Day #BILAG #lupus meeting in Leeds to enhance recruitment of @NIHRresearch FIRST and @VersusArthritis @NIHRresearch @The_MRC STRATIFY-LUPUS - two trials opening in UK in 2026. Discussed Treat-to-Target & inspiring the next generation Lupus Leaders @LUPUSUK 🦋

STRATIFY lupus: personalised care for patients | NIHR- a big thank you to all the lupus specialists and their patients who made this research possible as well as ⁦@VersusArthritis⁩ and ⁦@GSK⁩ nihr.ac.uk/story/stratify…

📷🎉Exciting news! Mike and I have been awarded a new grant to lead the STRATIFY Lupus—the FIRST EVER biomarker-enriched trial in lupus! We’ll use biomarkers (IgA2 anti-DNA) to predict who responds best to treatment. @VersusArthritis, @NIHRresearch EME, @GSK , and @LUPUSUK

NEW REVIEW—@LucyCarter6, @MikeEhrenstein & @edvital discuss the evolution and trajectory of B-cell targeted therapies in rheumatic diseases bit.ly/4hfPCP8

Research Fellow in immunology/rheumatology at UCL jobs.ac.uk/job/DLN096/res…

Exciting #researchopportunity to join our group to work on the #Immunology of #lupus working on biomarkers and mechanisms of response to B cell targeted therapies with @MuhammadShipa @louisakjames ucl.ac.uk/work-at-ucl/se…

Important research from @Dr_JohnR and colleagues highlighting the differences in management approaches for #lupus nephritis within the UK and that rituximab remains the most popular choice for refractory renal disease academic.oup.com/rheumap/articl…

Academic clinician–scientists risk becoming an endangered species. World View from @StephenORahilly @Cambridge_Uni nature.com/articles/s4159…

Very proud of @MuhammadShipa who successfully defended his thesis this afternoon. Well done! Thanks to @VersusArthritis and @LUPUSUK for supporting his research.

Clinical trials provide a unique substrate to understand pathogenesis and identify biomarkers to targeted therapies in #SLE which can be used to stratify patients. Taken from a new Viewpoint by @MikeEhrenstein ⁦and ⁦⁦@MuhammadShipa⁩: rupress.org/jem/article/22…

Well done ⁦@MuhammadShipa⁩ for the nomination from Department of Inflammation for the ⁦@DoM_UCL⁩ research award. Good luck! ucl.ac.uk/medicine/news-…

Andrew Pollard nails it again: The UK's NHS has transformed healthcare by training clinical research leaders, but they must have protected time to deliver. This cannot be achieved while doctors and nurses are drowning in a chronically understaffed system. theguardian.com/commentisfree/…

How experimental medicine can solve the challenge of modest efficacy and high cost drugs so that #lupus patients can access new treatments. ⁦@MuhammadShipa⁩ ⁦@VersusArthritis⁩ | Journal of Experimental Medicine | Rockefeller University Press rupress.org/jem/article/22…

.@MuhammadShipa presents an exploratory biomarker analysis of response to belimumab after rituximab from the BEAT-Lupus trial; baseline serum IgA2 anti-dsDNA and type 2 double neg memory B cells predict response #BSR23 #SLE @MikeEhrenstein See paper: thelancet.com/journals/lanrh…

Looking forward to #BSR23 next week 😃. We’ll have 3 x fantastic talks in the #lupus session. Hope to see you all there in person or virtually @RheumJnl @RheumatologyUK @MikeEhrenstein @edvital

Platinum Jubilee Chairs in rheumatology don’t come round very often. Closing date in 2 weeks. ⁦@ucl⁩ ⁦@uclmedsci⁩ ucl.ac.uk/work-at-ucl/se…